CLINICAL AND SEROLOGICAL RESPONSE TO THE PNEUMOCOCCAL VACCINATION AFTER CHEMOIMMUNOTHERAPY OR ON KINASE INHIBITORS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL).
| Componente | Categoria |
|---|---|
| Sara Pepe | Dottorando/Assegnista/Specializzando componente il gruppo di ricerca |
| Martina Canichella | Dottorando/Assegnista/Specializzando componente il gruppo di ricerca |
| Componente | Qualifica | Struttura | Categoria |
|---|---|---|---|
| Marta Coscia | ricercatore medico | Department of Hematology, University of Torino, A.O. Città della Salute e della Scienza, Turin | Altro personale Sapienza o esterni |
| Candida Vitale | ricercatore medico | Department of Hematology, University of Torino, A.O. Città della Salute e della Scienza, Turin | Altro personale Sapienza o esterni |
| Luca Laurenti | ricercatore medico | Department of Hematology and Stem Cell Transplantation Unit , Catholic University of Sacred Hearth. | Altro personale Sapienza o esterni |
| Idanna Innocenti | assegnista medico | Department of Hematology and Stem Cell Transplantation Unit , Catholic University of Sacred Hearth. | Altro personale Sapienza o esterni |
| Livio Trentin | ricercatore medico | Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Italy; | Altro personale Sapienza o esterni |
| Luca Visentin | ricercatore medico | Hematology and Clinical Immunology Unit, Department of Medicine, University of Padua, Italy; | Altro personale Sapienza o esterni |
| Diana Giannarelli | biostatistico | Biostatistic Unit, Regina Elena National Cancer Institute | Altro personale Sapienza o esterni |
| Silvia Baroncelli | ricercatore biologo | Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy | Altro personale Sapienza o esterni |
| Clementina Galluzzo | ricercatore biologo | Department of Therapeutic Research and Medicines Evaluation, Istituto Superiore di Sanità, Rome, Italy | Altro personale Sapienza o esterni |
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries, accounting for approximately 30% of all leukemias. Infections are the main cause of morbidity and mortality in patients with CLL.
Agents used in the management of CLL, especially steroids, purine analogues, alkylating agents and anti-CD20 monoclonal antibodies, contribute to the decrease in T cells and B cells, resulting in defects in humoral and cell-mediated immunity.
More than 20% treatment naive patients treated with FCR chemoimmunotherapy (fludarabina, cyclophosphamide, rituximab) and relapsed/refractory (R/R) patients treated with the BCR inhibitors develop severe infections, a pneumonia in the majority of the cases. Streptococcus pneumoniae (pneumococcus) constitutes a major global public health problem and is the most common cause of pneumonia. Conditions associated with immune deficiency greatly increase the likelihood of contracting pneumococcal disease. Growing resistance of pneumococcus to conventional antibiotics underlines the urgent need for vaccines to be used to control pneumococcal disease. Currently, pneumococcal vaccine is recommended in many countries and in Italy for patients with hematologic malignancy receiving immunocompromising therapy. However, data on the clinical benefit of vaccination in CLL patients is very limited. The present observational study will be carried out to define the clinical benefit and the serological response in previously untreated patients with CLL who receive the pneumococcal vaccine after the front-line FCR regimen and in R/R patients treated with the kinase inhibitors.